Hvivo Share Discussion Threads

[judijudi] 10/1/2023 08:51

😂🤣
But you sold half at 13.11 and 13.2

Great trading by the way 😂🤣
Does that mean you will stop pumping now you’ve sold out?
🤣😂

[baldrick1] 10/1/2023 08:48

Sold 2 lots of 50000 @15.26 and 15.33..just to wind up judi old lady.. and that's funny:)))

[judijudi] 10/1/2023 08:46

😂🤣
It gets even funnier 😂🤣
The share price is over 15p now
Keep going
Making my day 😂🤣

[baldrick1] 10/1/2023 08:40

I'm making £5000+so far..,funny for you?..I disposed half at 13.11 and 13.20..is that funny?

[baldrick1] 10/1/2023 08:29

Why you keep laughing old lady?:)))

[garth] 10/1/2023 08:21

"This award further strengthens our revenue visibility into 2024 and gives weight to the fact that we have a strong and sustainable growth model. The team has worked hard to achieve record numbers in 2022, and this award is the perfect start to 2023."

And,

"The Company also announces that it will provide a trading update for the year ended 31 December 2022 on 25 January 2023."

G.

[sev22] 10/1/2023 08:20

Profit from this fast-growing contract research business.

Simon Thompson highlights a specialist contract research organisation testing infectious and respiratory disease vaccines that has been winning a raft of contracts.

January 9, 2023
By Simon Thompson

*£5.2mn contract with global biotech company in Asia Pacific
*11 contract wins since start of 2022 worth £70.6mn
*95 per cent of 2023 revenue estimates already contracted

This could be a pivotal year for hVIVO (HVO:14p), a rapidly growing specialist contract research organisation (CRO) in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing early clinical development services for a broad and longstanding client base of biopharma companies.

Building on decades of experience, hVIVO is currently the only CRO focused on challenge studies, providing expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary.

hVIVO’s portfolio of human challenge study models for infectious and respiratory diseases include a recently established Covid-19 model, and several new models, such as one focused on malaria, to address the dramatic growth of the global infectious disease market. The group runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art Queen Mary BioEnterprises clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row.

Trusted partner.

As a trusted partner to the global biopharma industry, growth is being mainly driven by hVIVO’s market-leading competitive position as well as increasing demand for human challenge services in what is a rapidly expanding infectious and respiratory clinical trials market. To date, the group has completed more than 60 human challenge studies, inoculating more than 3,500 volunteers, and boasts four of the world’s top 10 biopharma giants as active clients. Contract momentum is building strongly, the latest win being a £5.2mn contract with a major client in Asia Pacific, the eleventh award and the eighth challenge study contract win since the start of 2022. In aggregate, these 11 contracts have a combined total disclosed value of £70.6mn, up from £48.3mn reported in 2021, giving a further boost to the record £80mn backlog of contracts that hVIVO reported in early September.

Furthermore, around 95 per cent of FinnCap’s current-year revenue estimate of £54mn is already covered by contracts, thus massively de-risking analysts’ estimates which point to both pre-tax profits and earnings per share (EPS) rising by more than a third to £5mn and 0.7p, respectively. It also means there is potential for earnings upgrades if the ongoing momentum is maintained, as seems likely. However, the shares are attractively priced even without upgrades.

Stripping out last year’s estimated closing net cash pile of £18.8mn (2.8p a share), the shares are priced on cash-adjusted price/earnings (PE) ratios of 16 (2023) and 14 (2024), hardly exacting for a business that is expected to deliver 60 per cent cumulative EPS growth over the 2022-24 forecast period. Moreover, that cash pile is expected to build to £22.8mn (2023) and then £26.9mn (2024) as highlighted by projected free cash flow yields of 4.7 per cent (2023) and 6.5 per cent (2024). On this basis, the cash-adjusted PE ratios drop to 15 and 12.5, respectively.

Attracting investors’ attention.

The strong earnings visibility, impressive contract momentum, operational leverage and rock-solid balance sheet are starting to attract investors’ attention, hence why hVIVO’s share price has risen 50 per cent since I initiated coverage (Alpha Research: ‘Ride the boom in vaccine research’, 17 November 2022). A chart break-out above the November high (14.5p) looks a real possibility, and would be a bullish signal worth following, opening the door to a run up to my conservative looking target price of 19p, well below those of Liberum Capital (21.6p) and FinnCap (44p). Buy.

[judijudi] 10/1/2023 08:15

😂🤣

[baldrick1] 10/1/2023 08:12

Should break thru 16p today

[sos100] 10/1/2023 08:04

we are massively undervalued....hope the market finally starts to see this

[owenski] 09/1/2023 18:18

The business per se isn't static either, the CEO is making his mark here.

[parob] 09/1/2023 18:14

Worth remembering that Simon Thompson's conservative 19p target doesn't attribute any value to DIM and HVO's share of Imutex and PrEP Bio.

[parob] 09/1/2023 16:49

Surprise surprise!Another Simon Thompson investors chronicle tip just out!Through 15p tomorrow?hTTps://www.investorschronicle.co.uk/ideas/2023/01/09/profit-from-this-fast-growing-contract-research-business/

[yump] 09/1/2023 16:37

Getting like a pawn broker's here. Buy on one counter for 12p and sell on the other one for 12.5p, then rinse and repeat.

[baldrick1] 09/1/2023 15:49

Could I ask even for 14.10p? ;)))

[baldrick1] 09/1/2023 15:41

Not finished burning up shorties at polb..

[baldrick1] 09/1/2023 15:23

Anyone agrees we could end the day @14.50..and why not? :)

[baldrick1] 09/1/2023 15:18

Wind up merchant you are old lady..;)))

[judijudi] 09/1/2023 15:13

Sold at 13.5 mid last week and brought back on Friday and now has a larger holding
😂🤣

[baldrick1] 09/1/2023 15:11

Expect more contract announcements very soon

[baldrick1] 09/1/2023 15:09

We speak the same language;)))

[judijudi] 09/1/2023 15:03

That your talking shyte 😂🤣